Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci dorośli (kobiety i mężczyźni).
- •Zaawansowany rak piersi (ER+/HER2-) nieuleczalny.
- •Choroba możliwa do oceny (widoczna na badaniach lub tylko zmiany w kościach).
- •Rak piersi zdiagnozowany jako zaawansowany od razu lub nawrót po co najmniej 12 miesiącach od leczenia hormonalnego.
- •Pacjenci w dobrym ogólnym stanie zdrowia (wg skali ECOG 0-1).
- •Wystarczająca ilość komórek krwi i prawidłowe wyniki badań wątroby i nerek.
- •Kobiety w każdym wieku (przed, w trakcie lub po menopauzie).
- •Mężczyźni i kobiety przed menopauzą muszą zgodzić się na dodatkowe leczenie hormonalne.
✗ Disqualifies
- •Nawrót choroby podczas leczenia hormonalnego.
- •Wcześniejsze leczenie systemowe zaawansowanego raka piersi (ER+/HER2-).
- •Wcześniejsze leczenie lekami: fulvestrant, elacestrant lub innymi eksperymentalnymi lekami hormonalnymi.
- •Uczulenie na leki badane w tym badaniu.
- •Przeciwwskazania do stosowania leków letrozol i rybociclib.
- •Aktywne przerzuty do mózgu lub rdzenia kręgowego wymagające natychmiastowego leczenia.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (150)
Clinical Trial Site
Hot Springs, United States
Clinical Trial Site
Beverly Hills, United States
Clinical Trial Site
San Francisco, United States
Clinical Trial Site
Santa Barbara, United States
Clinical Trial Site
Aurora, United States
Clinical Trial Site
Denver, United States
Clinical Trial Site
New Haven, United States
Clinical Trial Site
Tampa, United States
Clinical Trial Site
Marietta, United States
Clinical Trial Site
Honolulu, United States
Clinical Trial Site
Peoria, United States
Clinical Trial Site
Urbana, United States
Clinical Trial Site
Ames, United States
Clinical Trial Site
Scarborough, United States
Clinical Trial Site
Annapolis, United States
Clinical Trial Site
Minneapolis, United States
Clinical Trial Site
Kansas City, United States
Clinical Trial Site
Santa Fe, United States
Clinical Trial Site
New York, United States
Clinical Trial Site
Charlotte, United States
Clinical Trial Site
Cincinnati, United States
Clinical Trial Site
Columbus, United States
Clinical Trial Site
Horsham, United States
Clinical Trial Site
Sayre, United States
Clinical Trial Site
Bartlett, United States
Clinical Trial Site
Knoxville, United States
Clinical Trial Site
Mount Juliet, United States
Clinical Trial Site
Tennessee City, United States
Clinical Trial Site
Denton, United States
Clinical Trial Site
El Paso, United States
Clinical Trial Site
Houston, United States
Clinical Trial Site
San Antonio, United States
Clinical Trial Site
Salt Lake City, United States
Clinical Trial Site
Fort Belvoir, United States
Clinical Trial Site
Norfolk, United States
Clinical Trial Site
Olympia, United States
Clinical Trial Site
Vancouver, United States
Clinical Trial Site
Sydney, Australia
Clinical Trial Site
Waratah, Australia
Clinical Trial Site
South Brisbane, Australia
Clinical Trial Site
Adelaide, Australia
Clinical Trial Site
Clayton, Australia
Clinical Trial Site
Geelong, Australia
Clinical Trial Site
Heidelberg, Australia
Clinical Trial Site
Nedlands, Australia
Clinical Trial Site
Linz, Austria
Clinical Trial Site
Brussels, Belgium
Clinical Trial Site
Woluwe-Saint-Lambert, Belgium
Clinical Trial Site
Kortrijk, Belgium
Clinical Trial Site
Liège, Belgium
Clinical Trial Site
Charleroi, Belgium
Clinical Trial Site
Toronto, Canada
Clinical Trial Site
Hořovice, Czechia
Clinical Trial Site
Liberec, Czechia
Clinical Trial Site
Olomouc, Czechia
Clinical Trial Site
Prague, Czechia
Clinical Trial Site
Zlín, Czechia
Clinical Trial Site
Pierre-Bénite, France
Clinical Trial Site
Brest, France
Clinical Trial Site
Plérin, France
Clinical Trial Site
Besançon, France
Clinical Trial Site
Montpellier, France
Clinical Trial Site
Toulouse, France
Clinical Trial Site
Bobigny, France
Clinical Trial Site
Villejuif, France
Clinical Trial Site
Torgau, Germany
Clinical Trial Site
Pátrai, Greece
Clinical Trial Site
Athens, Greece
Clinical Trial Site
Athens, Greece
Clinical Trial Site
Thessaloniki, Greece
Clinical Trial Site
Hong Kong, Hong Kong
Clinical Trial Site
Hong Kong, Hong Kong
Clinical Trial Site
Hong Kong, Hong Kong
Clinical Trial Site
Kecskemét, Hungary
Clinical Trial Site
Debrecen, Hungary
Clinical Trial Site
Bologna, Italy
Clinical Trial Site
Rome, Italy
Clinical Trial Site
Genoa, Italy
Clinical Trial Site
Bergamo, Italy
Clinical Trial Site
Milan, Italy
Clinical Trial Site
Milan, Italy
Clinical Trial Site
Prato, Italy
Clinical Trial Site
Milan, Italy
Clinical Trial Site
Ipoh, Malaysia
Clinical Trial Site
Kuala Lumpur, Malaysia
Clinical Trial Site
Kuala Lumpur, Malaysia
Clinical Trial Site
George Town, Malaysia
Clinical Trial Site
Kota Kinabalu, Malaysia
Clinical Trial Site
Kuching, Malaysia
Clinical Trial Site
Petaling Jaya, Malaysia
Clinical Trial Site
Putrajaya, Malaysia
Clinical Trial Site
Apeldoorn, Netherlands
Clinical Trial Site
Maastricht, Netherlands
Clinical Trial Site
Amsterdam, Netherlands
Clinical Trial Site
Krakow, Poland
Clinical Trial Site
Rzeszów, Poland
Clinical Trial Site
Rzeszów, Poland
Clinical Trial Site
Brzozów, Poland
Clinical Trial Site
Lodz, Poland
Clinical Trial Site
Lisbon, Portugal
Clinical Trial Site
Porto, Portugal
Clinical Trial Site
Bucharest, Romania
Clinical Trial Site
Cluj-Napoca, Romania
Clinical Trial Site
Ovidiu, Romania
Clinical Trial Site
Craiova, Romania
Clinical Trial Site
Iași, Romania
Clinical Trial Site
Timișoara, Romania
Clinical Trial Site
Busan, South Korea
Clinical Trial Site
Daegu, South Korea
Clinical Trial Site
Goyang-si, South Korea
Clinical Trial Site
Seongnam-si, South Korea
Clinical Trial Site
Suwon, South Korea
Clinical Trial Site
Yongin-si, South Korea
Clinical Trial Site
Seoul, South Korea
Clinical Trial Site 1
Seoul, South Korea
Clinical Trial Site 2
Seoul, South Korea
Clinical Trial Site
Seoul, South Korea
Clinical Trial Site
Seoul, South Korea
Clinical Trial Site
Seoul, South Korea
Clinical Trial Site
Alicante, Spain
Clinical Trial Site
Barcelona, Spain
Clinical Trial Site
Barcelona, Spain
Clinical Trial Site
Barcelona, Spain
Clinical Trial Site
Granada, Spain
Clinical Trial Site
León, Spain
Clinical Trial Site
Lleida, Spain
Clinical Trial Site
Madrid, Spain
Clinical Trial Site
Madrid, Spain
Clinical Trial Site
Madrid, Spain
Clinical Trial Site
Madrid, Spain
Clinical Trial Site
Murcia, Spain
Clinical Trial Site
Seville, Spain
Clinical Trial Site
Valencia, Spain
Clinical Trial Site
Zaragoza, Spain
Clinical Trial Site
Chang-hua, Taiwan
Clinical Trial Site
Kaohsiung City, Taiwan
Clinical Trial Site
Taipei, Taiwan
Clinical Trial Site
Taipei, Taiwan
Clinical Trial Site
Taipei, Taiwan
Clinical Trial Site
Taipei, Taiwan
Clinical Trial Site
Bangkok, Thailand
Clinical Trial Site
Dusit, Thailand
Clinical Trial Site
Ban Phaeo, Thailand
Clinical Trial Site
Hat Yai, Thailand
Clinical Trial Site
Chiang Mai, Thailand
Clinical Trial Site
Brighton, United Kingdom
Clinical Trial Site
London, United Kingdom
Clinical Trial Site
London, United Kingdom
Clinical Trial Site
Taunton, United Kingdom
Clinical Trial Site
Guildford, United Kingdom
Trial contact
Olema Pharmaceuticals, Inc.
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.